Loading…
Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Background Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 a...
Saved in:
| Published in: | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020-07, Vol.23 (4), p.648-658 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3 |
| container_end_page | 658 |
| container_issue | 4 |
| container_start_page | 648 |
| container_title | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |
| container_volume | 23 |
| creator | Nakamura, Kenichi Hatakeyama, Keiichi Furukawa, Kenichiro Fujiya, Keiichi Kamiya, Satoshi Hikage, Makoto Tanizawa, Yutaka Bando, Etsuro Ohshima, Keiichi Urakami, Kenichi Machida, Nozomu Yasui, Hirofumi Yamaguchi, Ken Terashima, Masanori |
| description | Background
Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 adjuvant chemotherapy using comprehensive gene expression analysis.
Methods
We retrospectively analyzed 102 patients receiving adjuvant chemotherapy with S-1 and 46 patients not receiving S-1 adjuvant chemotherapy after gastrectomy for gastric cancer treatment between January 2014 and December 2016. Hierarchical clustering analysis was performed based on the gene expression data obtained using cDNA microarray. Differentially expressed genes (DEGs) were identified using thresholds of absolute fold changes of > 4.0 and a false discovery rate
P
value of |
| doi_str_mv | 10.1007/s10120-020-01056-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2378898536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2378898536</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EoqXwAhyQJS5cQv0nTpwjqqCNVAmkwjmaOJNdrzbO4nGq7hvw2DjaFiQOHEa27G--sfxj7K0UH6UQ9SVJIZUoxFpSmKqonrFzWeqq0FqY50971cgz9opoJ4Q0jaxesjOtpDXG2HP261vEwbvk58Dnkd8VksOwW-4hJO62OM1pixEOR95jwNEn7gO_S7BB3raXbdvyDVCK3nEHwWHkKSKkCXN3D4QDz1o3T4eIWwzk75FvsofjQz4hWodCgP2RPL1mL0bYE755XC_Yjy-fv1_dFLdfr9urT7eFK0udiqY31g2NQKP60WotKzBjZa3CUjoJui7rATUMpRJNMw5aONNYrXoQMLra9vqCfTh5D3H-uSClbvLkcL-HgPNCndK1tY01usro-3_Q3bzE_N5MldLkP6-MzZQ6US7ORBHH7hD9BPHYSdGtOXWnnDqx1ppTt6rfPaqXfsLhT8tTMBnQJ4DyVdhg_Dv7P9rfV46eaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2415010658</pqid></control><display><type>article</type><title>Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis</title><source>Springer Nature</source><creator>Nakamura, Kenichi ; Hatakeyama, Keiichi ; Furukawa, Kenichiro ; Fujiya, Keiichi ; Kamiya, Satoshi ; Hikage, Makoto ; Tanizawa, Yutaka ; Bando, Etsuro ; Ohshima, Keiichi ; Urakami, Kenichi ; Machida, Nozomu ; Yasui, Hirofumi ; Yamaguchi, Ken ; Terashima, Masanori</creator><creatorcontrib>Nakamura, Kenichi ; Hatakeyama, Keiichi ; Furukawa, Kenichiro ; Fujiya, Keiichi ; Kamiya, Satoshi ; Hikage, Makoto ; Tanizawa, Yutaka ; Bando, Etsuro ; Ohshima, Keiichi ; Urakami, Kenichi ; Machida, Nozomu ; Yasui, Hirofumi ; Yamaguchi, Ken ; Terashima, Masanori</creatorcontrib><description>Background
Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 adjuvant chemotherapy using comprehensive gene expression analysis.
Methods
We retrospectively analyzed 102 patients receiving adjuvant chemotherapy with S-1 and 46 patients not receiving S-1 adjuvant chemotherapy after gastrectomy for gastric cancer treatment between January 2014 and December 2016. Hierarchical clustering analysis was performed based on the gene expression data obtained using cDNA microarray. Differentially expressed genes (DEGs) were identified using thresholds of absolute fold changes of > 4.0 and a false discovery rate
P
value of < 0.01. Gene Ontology (GO) analysis and GO network visualization were performed using the ClueGO app in Cytoscape.
Results
Hierarchical clustering analysis in patients treated with S-1 adjuvant chemotherapy revealed two clusters with favorable and unfavorable survival outcomes. We identified 147 upregulated DEGs and 192 downregulated DEGs in the favorable outcome group. GO analysis to identify significantly upregulated genes showed enrichment in immune-related genes and GO terms. Upregulation of these immune-related genes was not associated with survival in patients not receiving S-1 adjuvant chemotherapy.
Conclusions
The upregulation and enrichment of immune-related genes and GO terms may be predictive biomarkers in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.</description><identifier>ISSN: 1436-3291</identifier><identifier>EISSN: 1436-3305</identifier><identifier>DOI: 10.1007/s10120-020-01056-6</identifier><identifier>PMID: 32185558</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Abdominal Surgery ; Biomarkers ; Cancer Research ; Cancer therapies ; Chemotherapy ; DNA microarrays ; Gastrectomy ; Gastric cancer ; Gastroenterology ; Gene expression ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Surgical Oncology ; Survival</subject><ispartof>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-07, Vol.23 (4), p.648-658</ispartof><rights>The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020</rights><rights>The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3</citedby><cites>FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3</cites><orcidid>0000-0002-2967-8267</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32185558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Kenichi</creatorcontrib><creatorcontrib>Hatakeyama, Keiichi</creatorcontrib><creatorcontrib>Furukawa, Kenichiro</creatorcontrib><creatorcontrib>Fujiya, Keiichi</creatorcontrib><creatorcontrib>Kamiya, Satoshi</creatorcontrib><creatorcontrib>Hikage, Makoto</creatorcontrib><creatorcontrib>Tanizawa, Yutaka</creatorcontrib><creatorcontrib>Bando, Etsuro</creatorcontrib><creatorcontrib>Ohshima, Keiichi</creatorcontrib><creatorcontrib>Urakami, Kenichi</creatorcontrib><creatorcontrib>Machida, Nozomu</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Yamaguchi, Ken</creatorcontrib><creatorcontrib>Terashima, Masanori</creatorcontrib><title>Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis</title><title>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</title><addtitle>Gastric Cancer</addtitle><addtitle>Gastric Cancer</addtitle><description>Background
Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 adjuvant chemotherapy using comprehensive gene expression analysis.
Methods
We retrospectively analyzed 102 patients receiving adjuvant chemotherapy with S-1 and 46 patients not receiving S-1 adjuvant chemotherapy after gastrectomy for gastric cancer treatment between January 2014 and December 2016. Hierarchical clustering analysis was performed based on the gene expression data obtained using cDNA microarray. Differentially expressed genes (DEGs) were identified using thresholds of absolute fold changes of > 4.0 and a false discovery rate
P
value of < 0.01. Gene Ontology (GO) analysis and GO network visualization were performed using the ClueGO app in Cytoscape.
Results
Hierarchical clustering analysis in patients treated with S-1 adjuvant chemotherapy revealed two clusters with favorable and unfavorable survival outcomes. We identified 147 upregulated DEGs and 192 downregulated DEGs in the favorable outcome group. GO analysis to identify significantly upregulated genes showed enrichment in immune-related genes and GO terms. Upregulation of these immune-related genes was not associated with survival in patients not receiving S-1 adjuvant chemotherapy.
Conclusions
The upregulation and enrichment of immune-related genes and GO terms may be predictive biomarkers in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.</description><subject>Abdominal Surgery</subject><subject>Biomarkers</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>DNA microarrays</subject><subject>Gastrectomy</subject><subject>Gastric cancer</subject><subject>Gastroenterology</subject><subject>Gene expression</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Surgical Oncology</subject><subject>Survival</subject><issn>1436-3291</issn><issn>1436-3305</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQhy0EoqXwAhyQJS5cQv0nTpwjqqCNVAmkwjmaOJNdrzbO4nGq7hvw2DjaFiQOHEa27G--sfxj7K0UH6UQ9SVJIZUoxFpSmKqonrFzWeqq0FqY50971cgz9opoJ4Q0jaxesjOtpDXG2HP261vEwbvk58Dnkd8VksOwW-4hJO62OM1pixEOR95jwNEn7gO_S7BB3raXbdvyDVCK3nEHwWHkKSKkCXN3D4QDz1o3T4eIWwzk75FvsofjQz4hWodCgP2RPL1mL0bYE755XC_Yjy-fv1_dFLdfr9urT7eFK0udiqY31g2NQKP60WotKzBjZa3CUjoJui7rATUMpRJNMw5aONNYrXoQMLra9vqCfTh5D3H-uSClbvLkcL-HgPNCndK1tY01usro-3_Q3bzE_N5MldLkP6-MzZQ6US7ORBHH7hD9BPHYSdGtOXWnnDqx1ppTt6rfPaqXfsLhT8tTMBnQJ4DyVdhg_Dv7P9rfV46eaQ</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Nakamura, Kenichi</creator><creator>Hatakeyama, Keiichi</creator><creator>Furukawa, Kenichiro</creator><creator>Fujiya, Keiichi</creator><creator>Kamiya, Satoshi</creator><creator>Hikage, Makoto</creator><creator>Tanizawa, Yutaka</creator><creator>Bando, Etsuro</creator><creator>Ohshima, Keiichi</creator><creator>Urakami, Kenichi</creator><creator>Machida, Nozomu</creator><creator>Yasui, Hirofumi</creator><creator>Yamaguchi, Ken</creator><creator>Terashima, Masanori</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2967-8267</orcidid></search><sort><creationdate>20200701</creationdate><title>Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis</title><author>Nakamura, Kenichi ; Hatakeyama, Keiichi ; Furukawa, Kenichiro ; Fujiya, Keiichi ; Kamiya, Satoshi ; Hikage, Makoto ; Tanizawa, Yutaka ; Bando, Etsuro ; Ohshima, Keiichi ; Urakami, Kenichi ; Machida, Nozomu ; Yasui, Hirofumi ; Yamaguchi, Ken ; Terashima, Masanori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abdominal Surgery</topic><topic>Biomarkers</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>DNA microarrays</topic><topic>Gastrectomy</topic><topic>Gastric cancer</topic><topic>Gastroenterology</topic><topic>Gene expression</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Surgical Oncology</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Kenichi</creatorcontrib><creatorcontrib>Hatakeyama, Keiichi</creatorcontrib><creatorcontrib>Furukawa, Kenichiro</creatorcontrib><creatorcontrib>Fujiya, Keiichi</creatorcontrib><creatorcontrib>Kamiya, Satoshi</creatorcontrib><creatorcontrib>Hikage, Makoto</creatorcontrib><creatorcontrib>Tanizawa, Yutaka</creatorcontrib><creatorcontrib>Bando, Etsuro</creatorcontrib><creatorcontrib>Ohshima, Keiichi</creatorcontrib><creatorcontrib>Urakami, Kenichi</creatorcontrib><creatorcontrib>Machida, Nozomu</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Yamaguchi, Ken</creatorcontrib><creatorcontrib>Terashima, Masanori</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Kenichi</au><au>Hatakeyama, Keiichi</au><au>Furukawa, Kenichiro</au><au>Fujiya, Keiichi</au><au>Kamiya, Satoshi</au><au>Hikage, Makoto</au><au>Tanizawa, Yutaka</au><au>Bando, Etsuro</au><au>Ohshima, Keiichi</au><au>Urakami, Kenichi</au><au>Machida, Nozomu</au><au>Yasui, Hirofumi</au><au>Yamaguchi, Ken</au><au>Terashima, Masanori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis</atitle><jtitle>Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association</jtitle><stitle>Gastric Cancer</stitle><addtitle>Gastric Cancer</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>23</volume><issue>4</issue><spage>648</spage><epage>658</epage><pages>648-658</pages><issn>1436-3291</issn><eissn>1436-3305</eissn><abstract>Background
Studies to identify predictive biomarkers of adjuvant chemotherapy with S-1 after gastrectomy in Stage II/III gastric cancer patients have been done; however, more clarity and understanding are needed. Our aim in the present study was to identify biomarkers predicting benefit due to S-1 adjuvant chemotherapy using comprehensive gene expression analysis.
Methods
We retrospectively analyzed 102 patients receiving adjuvant chemotherapy with S-1 and 46 patients not receiving S-1 adjuvant chemotherapy after gastrectomy for gastric cancer treatment between January 2014 and December 2016. Hierarchical clustering analysis was performed based on the gene expression data obtained using cDNA microarray. Differentially expressed genes (DEGs) were identified using thresholds of absolute fold changes of > 4.0 and a false discovery rate
P
value of < 0.01. Gene Ontology (GO) analysis and GO network visualization were performed using the ClueGO app in Cytoscape.
Results
Hierarchical clustering analysis in patients treated with S-1 adjuvant chemotherapy revealed two clusters with favorable and unfavorable survival outcomes. We identified 147 upregulated DEGs and 192 downregulated DEGs in the favorable outcome group. GO analysis to identify significantly upregulated genes showed enrichment in immune-related genes and GO terms. Upregulation of these immune-related genes was not associated with survival in patients not receiving S-1 adjuvant chemotherapy.
Conclusions
The upregulation and enrichment of immune-related genes and GO terms may be predictive biomarkers in patients who would benefit from adjuvant S-1 chemotherapy to treat Stage II/III gastric cancer.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32185558</pmid><doi>10.1007/s10120-020-01056-6</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2967-8267</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1436-3291 |
| ispartof | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-07, Vol.23 (4), p.648-658 |
| issn | 1436-3291 1436-3305 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2378898536 |
| source | Springer Nature |
| subjects | Abdominal Surgery Biomarkers Cancer Research Cancer therapies Chemotherapy DNA microarrays Gastrectomy Gastric cancer Gastroenterology Gene expression Medicine Medicine & Public Health Oncology Original Article Surgical Oncology Survival |
| title | Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A39%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20S-1%20adjuvant%20chemotherapy%20benefit%20in%20Stage%20II/III%20gastric%20cancer%20treatment%20based%20on%20comprehensive%20gene%20expression%20analysis&rft.jtitle=Gastric%20cancer%20:%20official%20journal%20of%20the%20International%20Gastric%20Cancer%20Association%20and%20the%20Japanese%20Gastric%20Cancer%20Association&rft.au=Nakamura,%20Kenichi&rft.date=2020-07-01&rft.volume=23&rft.issue=4&rft.spage=648&rft.epage=658&rft.pages=648-658&rft.issn=1436-3291&rft.eissn=1436-3305&rft_id=info:doi/10.1007/s10120-020-01056-6&rft_dat=%3Cproquest_cross%3E2378898536%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-9b58cd90e52bf83316a5f6882e41c1a3747de3ad42099fd30c59832ba0afc78b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2415010658&rft_id=info:pmid/32185558&rfr_iscdi=true |